eligibility_summary
Age ≥18 (≥20 if enrolled before 2023), severe uncontrolled asthma on medium/high-dose ICS+LABA, prescribed but not yet started reimbursed benralizumab, consent and able to complete ACQ-5/PGI-C/PGI-S. Reimbursement: ≥2 exacerbations/12 mo (≥1 ED/hosp), ≥6 mo maintenance OCS ≥5 mg/d, eos ≥300/μL. Exclude: other lung disease, interventional trial (except registry/completed), limiting conditions, concurrent biologics (≥30-day washout), on benralizumab or <6 mo since prior.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
- Drug/intervention: Benralizumab (Fasenra), an afucosylated humanized IgG1 monoclonal antibody biologic. Mechanism: binds IL‑5 receptor alpha (IL‑5Rα) on eosinophils (and basophils), blocking IL‑5 signaling and inducing potent antibody‑dependent cell‑mediated cytotoxicity (ADCC), leading to near‑complete eosinophil depletion and reduction of type 2 inflammation. - Cells/pathways targeted: Eosinophils (primary) and basophils via IL‑5/IL‑5R pathway, NK cells act as ADCC effectors. - Context: Real‑world, open‑label, single‑arm, non‑interventional study in Taiwan assessing use, effectiveness, and patient‑reported outcomes in severe uncontrolled eosinophilic asthma receiving reimbursed benralizumab.